News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
712,065 Results
Type
Article (42180)
Company Profile (436)
Press Release (669449)
Section
Business (208681)
Career Advice (2021)
Deals (36001)
Drug Delivery (103)
Drug Development (83543)
Employer Resources (173)
FDA (16405)
Job Trends (15084)
News (352664)
Policy (33047)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (6)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (2635)
Accelerated approval (3)
Adcomms (24)
Allergies (82)
Alliances (50895)
ALS (88)
Alzheimer's disease (1406)
Antibody-drug conjugate (ADC) (123)
Approvals (16393)
Artificial intelligence (246)
Autoimmune disease (19)
Automation (14)
Bankruptcy (371)
Best Places to Work (11841)
BIOSECURE Act (18)
Biosimilars (102)
Biotechnology (330)
Bladder cancer (63)
Brain cancer (24)
Breast cancer (256)
Cancer (2059)
Cardiovascular disease (173)
Career advice (1686)
Career pathing (29)
CAR-T (146)
Cell therapy (418)
Cervical cancer (19)
Clinical research (67518)
Collaboration (809)
Compensation (461)
Complete response letters (24)
COVID-19 (2640)
CRISPR (40)
C-suite (223)
Cystic fibrosis (103)
Data (1995)
Decentralized trials (2)
Denatured (26)
Depression (46)
Diabetes (254)
Diagnostics (6393)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (118)
Drug pricing (104)
Drug shortages (26)
Duchenne muscular dystrophy (91)
Earnings (87448)
Editorial (35)
Employer branding (21)
Employer resources (147)
Events (115221)
Executive appointments (663)
FDA (17535)
Featured Employer (54)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (722)
Gene editing (104)
Generative AI (19)
Gene therapy (302)
GLP-1 (724)
Government (4467)
Grass and pollen (4)
Guidances (48)
Healthcare (19140)
Huntington's disease (23)
IgA nephropathy (25)
Immunology and inflammation (114)
Indications (27)
Infectious disease (2774)
Inflammatory bowel disease (138)
Inflation Reduction Act (11)
Influenza (48)
Intellectual property (88)
Interviews (311)
IPO (16766)
IRA (43)
Job creations (3699)
Job search strategy (1434)
Kidney cancer (9)
Labor market (34)
Layoffs (482)
Leadership (16)
Legal (7977)
Liver cancer (71)
Lung cancer (298)
Lymphoma (136)
Machine learning (4)
Management (58)
Manufacturing (276)
MASH (64)
Medical device (13472)
Medtech (13477)
Mergers & acquisitions (19704)
Metabolic disorders (667)
Multiple sclerosis (72)
NASH (19)
Neurodegenerative disease (91)
Neuropsychiatric disorders (30)
Neuroscience (1918)
NextGen: Class of 2025 (6755)
Non-profit (4546)
Northern California (2460)
Now hiring (37)
Obesity (362)
Opinion (220)
Ovarian cancer (74)
Pain (81)
Pancreatic cancer (77)
Parkinson's disease (140)
Partnered (20)
Patents (206)
Patient recruitment (94)
Peanut (47)
People (58477)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21211)
Phase II (29797)
Phase III (22035)
Pipeline (1066)
Podcasts (74)
Policy (121)
Postmarket research (2601)
Preclinical (9048)
Press Release (67)
Prostate cancer (97)
Psychedelics (37)
Radiopharmaceuticals (261)
Rare diseases (381)
Real estate (6008)
Recruiting (66)
Regulatory (22607)
Reports (46)
Research institute (2414)
Resumes & cover letters (351)
Rett syndrome (3)
RNA editing (4)
RSV (39)
Schizophrenia (72)
Series A (129)
Series B (84)
Service/supplier (11)
Sickle cell disease (56)
Southern California (2143)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (29)
Startups (3757)
State (2)
Stomach cancer (14)
Supply chain (60)
The Weekly (46)
United States (21783)
Vaccines (676)
Venture capitalists (38)
Webinars (13)
Weight loss (244)
Women's health (35)
Worklife (16)
Date
Today (159)
Last 7 days (766)
Last 30 days (2885)
Last 365 days (34635)
2025 (8346)
2024 (36301)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (736)
Alabama (54)
Alaska (7)
Arizona (232)
Arkansas (14)
Asia (39121)
Australia (6513)
California (5671)
Canada (1883)
China (486)
Colorado (254)
Connecticut (268)
Delaware (131)
Europe (85407)
Florida (826)
Georgia (194)
Idaho (57)
Illinois (516)
India (23)
Indiana (294)
Iowa (10)
Japan (144)
Kansas (103)
Kentucky (24)
Louisiana (8)
Maine (60)
Maryland (850)
Massachusetts (4347)
Michigan (211)
Minnesota (376)
Mississippi (2)
Missouri (78)
Montana (29)
Nebraska (25)
Nevada (56)
New Hampshire (66)
New Jersey (1617)
New Mexico (30)
New York (1619)
North Carolina (986)
North Dakota (7)
Northern California (2460)
Ohio (194)
Oklahoma (14)
Oregon (37)
Pennsylvania (1273)
Puerto Rico (9)
Rhode Island (27)
South America (1108)
South Carolina (18)
South Dakota (1)
Southern California (2143)
Tennessee (93)
Texas (846)
Utah (167)
Virginia (134)
Washington D.C. (59)
Washington State (531)
West Virginia (3)
Wisconsin (50)
712,065 Results for "corcept therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
March 31, 2025
·
6 min read
Press Releases
Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension
March 10, 2025
·
3 min read
Press Releases
FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism
March 3, 2025
·
3 min read
Press Releases
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update
February 26, 2025
·
10 min read
Press Releases
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call
February 12, 2025
·
1 min read
Drug Development
Corcept Completes Enrollment in Phase 4 CATALYST Trial
Corcept Therapeutics Incorporated today announced completion of enrollment in CATALYST, a Phase 4 trial examining the prevalence of hypercortisolism.
April 29, 2024
·
3 min read
Business
Corcept Therapeutics to Announce First Quarter 2024 Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics Incorporated announced it will report first quarter financial results and provide a corporate update on May 1, 2024.
April 24, 2024
·
1 min read
Drug Development
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
Corcept Therapeutics Incorporated today announced that the results from GRACE, the Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with hypercortisolism (Cushing’s syndrome).
June 3, 2024
·
3 min read
Business
Corcept Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, reported its results for the quarter ended March 31, 2024.
May 1, 2024
·
10 min read
Press Releases
Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism
December 16, 2024
·
5 min read
1 of 71,207
Next
